News Headlines Article

Drugmaker revives obesity pill rejected by FDA
USA Today

Orexigen Therapeutics Inc. said Tuesday it is reviving its previously abandoned weight loss drug Contrave, after federal health officials outlined a plan that could bring the drug to market by 2014. The surprise announcement returns Contrave to the race to be the first new prescription weight loss drug to reach the U.S. market in more than a decade. Company shares leapt 95 cents, or 64.6 percent, to $2.42 in afterhours trading. The stock was trading in the $9 range before the FDA rejection of Contrave, which wiped out about two-thirds of its value.